Modelling Health State Utilities as a Transformation of Time to Death in Patients with Non-Small Cell Lung Cancer.
Journal
PharmacoEconomics
ISSN: 1179-2027
Titre abrégé: Pharmacoeconomics
Pays: New Zealand
ID NLM: 9212404
Informations de publication
Date de publication:
14 Sep 2023
14 Sep 2023
Historique:
accepted:
14
08
2023
medline:
14
9
2023
pubmed:
14
9
2023
entrez:
14
9
2023
Statut:
aheadofprint
Résumé
When utilities are analyzed by time to death (TTD), this has historically been implemented by 'grouping' observations as discrete time periods to create health state utilities. We extended the approach to use continuous functions, avoiding assumptions around groupings. The resulting models were used to test the concept with data from different regions and different country tariffs. Five-year follow-up in advanced non-small cell lung cancer (NSCLC) was used to fit six continuous TTD models using generalized estimating equations, which were compared with progression-based utilities and previously published TTD groupings. Sensitivity analyses were performed using only patients with a confirmed death, the last year of life only, and artificially censoring data at 24 months. The statistically best-fitting model was then applied to data subsets by region and different EQ-5D-3L country tariffs. Continuous (natural) [Formula: see text] and [Formula: see text] models outperformed other continuous models, grouped TTD, and progression-based models in statistical fit (mean absolute error and Quasi Information Criterion). This held through sensitivity and scenario analyses. The pattern of reduced utility as a patient approaches death was consistent across regions and EQ-5D tariffs using the preferred [Formula: see text] model. The use of continuous models provides a statistically better fit than TTD groupings, without the need for strong assumptions about the health states experienced by patients. Where a TTD approach is merited for use in modelling, continuous functions should be considered, with the scope for further improvements in statistical fit by both widening the number of candidate models tested and the therapeutic areas investigated.
Sections du résumé
BACKGROUND
BACKGROUND
When utilities are analyzed by time to death (TTD), this has historically been implemented by 'grouping' observations as discrete time periods to create health state utilities. We extended the approach to use continuous functions, avoiding assumptions around groupings. The resulting models were used to test the concept with data from different regions and different country tariffs.
METHODS
METHODS
Five-year follow-up in advanced non-small cell lung cancer (NSCLC) was used to fit six continuous TTD models using generalized estimating equations, which were compared with progression-based utilities and previously published TTD groupings. Sensitivity analyses were performed using only patients with a confirmed death, the last year of life only, and artificially censoring data at 24 months. The statistically best-fitting model was then applied to data subsets by region and different EQ-5D-3L country tariffs.
RESULTS
RESULTS
Continuous (natural) [Formula: see text] and [Formula: see text] models outperformed other continuous models, grouped TTD, and progression-based models in statistical fit (mean absolute error and Quasi Information Criterion). This held through sensitivity and scenario analyses. The pattern of reduced utility as a patient approaches death was consistent across regions and EQ-5D tariffs using the preferred [Formula: see text] model.
CONCLUSIONS
CONCLUSIONS
The use of continuous models provides a statistically better fit than TTD groupings, without the need for strong assumptions about the health states experienced by patients. Where a TTD approach is merited for use in modelling, continuous functions should be considered, with the scope for further improvements in statistical fit by both widening the number of candidate models tested and the therapeutic areas investigated.
Identifiants
pubmed: 37707719
doi: 10.1007/s40273-023-01314-2
pii: 10.1007/s40273-023-01314-2
doi:
Types de publication
Journal Article
Langues
eng
Informations de copyright
© 2023. The Author(s).
Références
Kapetanakis V, Prawitz T, Schlichting M, Ishak KJ, Phatak H, Kearney M, et al. Assessment-schedule matching in unanchored indirect treatment comparisons of progression-free survival in cancer studies. Pharmacoeconomics. 2019;37:1537–51.
doi: 10.1007/s40273-019-00831-3
pubmed: 31555968
Hatswell AJ, Pennington B, Pericleous L, Rowen D, Lebmeier M, Lee D. Patient-reported utilities in advanced or metastatic melanoma, including analysis of utilities by time to death. Health Qual Life Outcomes. 2014;12:140.
doi: 10.1186/s12955-014-0140-1
pubmed: 25214238
pmcid: 4173059
Versteegh M, van der Helm I, Mokri H, Oerlemans S, Blommestein H, van Baal P. Estimating quality of life decrements in oncology using time to death. Value Health. 2022;25(10):1673–7.
doi: 10.1016/j.jval.2022.06.002
pubmed: 35803844
Lorem G, Cook S, Leon DA, Emaus N, Schirmer H. Self-reported health as a predictor of mortality: a cohort study of its relation to other health measurements and observation time. Sci Rep. 2020;10:4886.
doi: 10.1038/s41598-020-61603-0
pubmed: 32184429
pmcid: 7078209
Geue C, Lorgelly P, Lewsey J, Hart C, Briggs A. Hospital expenditure at the end-of-life: what are the impacts of health status and health risks? PLoS ONE. 2015;10: e0119035.
doi: 10.1371/journal.pone.0119035
pubmed: 25746728
pmcid: 4352086
Howdon D, Rice N. Health care expenditures, age, proximity to death and morbidity: implications for an ageing population. J Health Econ. 2018;57:60–74.
doi: 10.1016/j.jhealeco.2017.11.001
pubmed: 29182935
Hatswell AJ, Bullement A, Schlichting M, Bharmal M. What is the impact of the analysis method used for health state utility values on QALYs in oncology? A simulation study comparing progression-based and time-to-death approaches. Appl Health Econ Health Policy. 2021;19:389–401.
doi: 10.1007/s40258-020-00620-6
pubmed: 33314001
Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. improved survival with ipilimumab in patients with metastatic melanoma [cited 7 Jun 2019]. N Engl J Med. 2010;363:711–723. Available at: https://www.nejm.org/doi/ https://doi.org/10.1056/NEJMoa1003466?url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub%3Dwww.ncbi.nlm.nih.gov
Borghaei H, Gettinger S, Vokes EE, Chow LQM, Burgio MA, de Castro CJ, et al. Five-year outcomes from the randomized, phase III trials CheckMate 017 and 057: nivolumab versus docetaxel in previously treated non-small-cell lung cancer. J Clin Oncol. 2021;39:723–33.
doi: 10.1200/JCO.20.01605
pubmed: 33449799
pmcid: 8078445
Chaudhary M, Sun X, Yuan Y, Varol N, Penrod JR. PCN91 estimating EQ-5D utilities for cost-effectiveness models involving immuno-oncology treatments. Value Health. 2020;23(2):S438.
doi: 10.1016/j.jval.2020.08.228
Alava MH, Wailoo AJ, Ara R. Tails from the peak district: adjusted limited dependent variable mixture models of EQ-5D questionnaire health state utility values. Value Health. 2012;15:550–61.
doi: 10.1016/j.jval.2011.12.014
Ngo PJ, Wade S, Banks E, Karikios DJ, Canfell K, Weber MF. Large-scale population-based surveys linked to administrative health databases as a source of data on health utilities in Australia. Value Health. 2022;25:1634–43.
doi: 10.1016/j.jval.2022.03.026
pubmed: 35527166